‘We’re ahead of the pack’ in cannabinoid therapies

By taking a risk in 2014 and building a company around a single manmade cannabinoid, drugmaker Corbus Pharmaceuticals is now ahead of its larger peers on a number of key treatments, CEO Yuval Cohen said Thursday.

Source link

Leave a Comment

How China's GPS 'rival' Beidou is plotting to go globalAsian stocks extend recovery, China rallies on stimulus hopes